1. Home
  2. NEXT vs MPLT Comparison

NEXT vs MPLT Comparison

Compare NEXT & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

SELL

Current Price

$6.80

Market Cap

2.0B

Sector

Energy

ML Signal

SELL

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$7.88

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXT
MPLT
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
NEXT
MPLT
Price
$6.80
$7.88
Analyst Decision
Buy
Strong Buy
Analyst Count
5
15
Target Price
$8.70
★ $26.54
AVG Volume (30 Days)
★ 2.3M
417.6K
Earning Date
10-29-2026
12-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.39
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.75
$8.48
52 Week High
$9.24
$40.43

Technical Indicators

Market Signals
Indicator
NEXT
MPLT
Relative Strength Index (RSI) 50.20 22.51
Support Level $6.14 N/A
Resistance Level $7.79 $20.46
Average True Range (ATR) 0.26 0.58
MACD 0.04 -0.02
Stochastic Oscillator 83.33 0.34

Price Performance

Historical Comparison
NEXT
MPLT

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: